As of close of business last night, Brainstorm Cell Therapeutics, Inc.’s stock clocked out at $0.48, down -5.33% from its previous closing price of $0.51. In other words, the price has decreased by -$0.0270 from its previous closing price. On the day, 1795152 shares were traded.
Ratios:
To gain a deeper understanding of BCLI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.24 and its Current Ratio is at 0.24.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 01 ’23 when Lindborg Stacy bought 11,500 shares for $1.77 per share. The transaction valued at 20,402 led to the insider holds 181,500 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 24.50M and an Enterprise Value of 25.97M.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $3.46, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 0.3514, while the 200-Day Moving Average is calculated to be 0.8561.
Shares Statistics:
It appears that BCLI traded 1.37M shares on average per day over the past three months and 969.04k shares per day over the past ten days. A total of 48.98M shares are outstanding, with a floating share count of 40.23M. Insiders hold about 17.86% of the company’s shares, while institutions hold 8.09% stake in the company. Shares short for BCLI as of Feb 29, 2024 were 1.07M with a Short Ratio of 0.78, compared to 2.03M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.18% and a Short% of Float of 2.29%.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.7 and -$0.7 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.47, with 1 analysts recommending between -$0.47 and -$0.47.
